Staphylococcal Disease

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.

New Staph Vaccine Shows Promise in Rabbits

Staph infections pose one of the most serious microbial threats to people. Yet efforts to prevent them with vaccines have consistently failed, even as the bacterium responsible becomes increasingly resistant to antibiotics. Now, an experimental vaccine with novel ingredients has proven highly protective in rabbits against staph pneumonia, one of the most dangerous outcomes of the bacterial infection. The inventor hopes to take it into human studies soon.


Pfizer details plans to expand vaccine portfolio beyond Prevnar

Pfizer ($PFE) is an unusual player in the vaccine space. It is the fourth biggest vaccine company by revenue, yet almost wholly reliant on one product--Prevnar 13. At a media event in New York this week, the company's top brass explained how they plan to build out the business in the coming years.